Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer

Cytokine

Volumn 89, Issue , 2017, Pages 76-81

  Zhao, Zhonghua ^a,b   Chen, Xi ^a   Hao, Shengnan ^a   Jia, Rui ^b   Wang, Nana ^b   Chen, Shaoshui ^b   Li, Mianli ^b   Wang, Chuanxin ^a   Mao, Haiting ^a  

^a SHANDONG UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Interleukin 35; Invasive ductal carcinoma; Tumor infiltrating lymphocytes

Indexed keywords

ESTROGEN RECEPTOR; INTERLEUKIN 35; TUMOR MARKER; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; BIOSYNTHESIS; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; REGULATORY T LYMPHOCYTE; SURVIVAL RATE;

ADULT; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKINS; MIDDLE AGED; NEOPLASM PROTEINS; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY;

EID: 84996503957     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.09.012     Document Type: Article

References (28)

1. [1] Whiteside, T.L., Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol., 16, 2006, 3.
2. [2] Facciabene, A., Motz, G.T., Coukos, G., T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res., 72, 2012, 2162.
3. [3] Gooden, M.J., de Bock, G.H., Leffers, N., Daemen, T., Nijman, H.W., The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer, 105, 2011, 93.
4. [4] Lee, H.J., Seo, J.Y., Ahn, J.H., Ahn, S.H., Gong, G., Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J. Breast Cancer, 16, 2013, 32.
5. [5] Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol., 31, 2013, 860.
6. [6] Liu, C., Workman, C.J., Vignali, D.A., Targeting regulatory T cells in tumors. FEBS J., 2016.
7. [7] Klabusay, M., The role of regulatory T-cells in antitumor immune response. Klin. Onkol., 28(Suppl 4), 2015, 4S23.
8. [8] Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature, 450, 2007, 566.
9. [9] Devergne, O., Birkenbach, M., Kieff, E., Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc. Natl. Acad. Sci. USA, 94, 1997, 12041.
10. [10] Collison, L.W., Chaturvedi, V., Henderson, A.L., Giacomin, P.R., Guy, C., Bankoti, J., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol., 11, 2010, 1093.
11. + regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J. Immunol., 189, 2012, 5590.
12. [12] Shen, P., Roch, T., Lampropoulou, V., O'Connor, R.A., Stervbo, U., Hilgenberg, E., et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature, 507, 2014, 366.
13. [13] Wang, R.X., Yu, C.R., Dambuza, I.M., Mahdi, R.M., Dolinska, M.B., Sergeev, Y.V., et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med., 20, 2014, 633.
14. [14] Long, J., Zhang, X., Wen, M., Kong, Q., Lv, Z., An, Y., et al. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem. Biophys. Res. Commun., 430, 2013, 364.
15. [15] Mao, H., Gao, W., Ma, C., Sun, J., Liu, J., Shao, Q., et al. Human placental trophoblasts express the immunosuppressive cytokine IL-35. Hum. Immunol., 74, 2013, 872.
16. [16] Wang, Z., Liu, J.Q., Liu, Z., Shen, R., Zhang, G., Xu, J., et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J. Immunol., 190, 2013, 2415.
17. [17] Zeng, J.C., Zhang, Z., Li, T.Y., Liang, Y.F., Wang, H.M., Bao, J.J., et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int. J. Clin. Exp. Pathol., 6, 2013, 1806.
18. [18] Hamidinia, M., Ghafourian Boroujerdnia, M., Talaiezadeh, A., Solgi, G., Roshani, R., Iranprast, S., et al. Increased P-35, EBI3 transcripts and other treg markers in peripheral blood mononuclear cells of breast cancer patients with different clinical stages. Adv. Pharm. Bull., 5, 2015, 261.
19. [19] Chen, G., Liang, Y., Guan, X., Chen, H., Liu, Q., Lin, B., et al. Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosis in breast cancer. Am. J. Transl. Res., 8, 2016, 2255.
20. [20] Cao, X., Regulatory T cells and immune tolerance to tumors. Immunol. Res., 46, 2010, 79.
21. [21] Nishikawa, H., Sakaguchi, S., Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol., 27, 2014, 1.
22. [22] Vignali, D.A., Collison, L.W., Workman, C.J., How regulatory T cells work. Nat. Rev. Immunol., 8, 2008, 523.
23. [23] West, N.R., Milne, K., Truong, P.T., Macpherson, N., Nelson, B.H., Watson, P.H., Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res., 13, 2011, R126.
24. [24] Dieci, M.V., Griguolo, G., Miglietta, F., Guarneri, V., The immune system and hormone-receptor positive breast cancer: is it really a dead end?. Cancer Treat. Rev., 46, 2016, 9.
25. [25] Turnis, M.E., Sawant, D.V., Szymczak-Workman, A.L., Andrews, L.P., Delgoffe, G.M., Yano, H., et al. Interleukin-35 limits anti-tumor immunity. Immunity, 44, 2016, 316.
26. [26] Whitford, P., Mallon, E.A., George, W.D., Campbell, A.M., Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br. J. Cancer, 62, 1990, 971.
27. [27] Sawant, D.V., Hamilton, K., Vignali, D.A., Interleukin-35: expanding its job profile. J. Interferon Cytokine Res., 35, 2015, 499.
28. [28] Gu, X., Tian, T., Zhang, B., Liu, Y., Yuan, C., Shao, L., et al. Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer. Tumour Biol., 36, 2015, 2651.